Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

Abstract Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of ad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 2023-07, Vol.115 (7), p.870-880
Hauptverfasser: Spencer, Kristen, Pappas, Leontios, Baiev, Islam, Maurer, Jordan, Bocobo, Andrea Grace, Zhang, Karen, Jain, Apurva, De Armas, Anaemy Danner, Reyes, Stephanie, Le, Tri Minh, Rahma, Osama E, Stanton, Jennifer, DeLeon, Thomas T, Roth, Marc, Peters, Mary Linton B, Zhu, Andrew X, Lennerz, Jochen K, Iafrate, A John, Boyhen, Kylie, VanCott, Christine, Roberts, Lewis R, Lindsey, Stacie, Horick, Nora, Goff, Laura Williams, Mody, Kabir, Borad, Mitesh J, Shroff, Rachna T, Kelley, Robin Kate, Javle, Milind M, Goyal, Lipika
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of adjuvant, liver-directed, targeted, and investigational therapies. Methods This multicenter collaboration included patients with ICC or ECC treated at 1 of 8 participating institutions. Retrospective data were collected on risk factors, pathology, treatments, and survival. Comparative statistical tests were 2-sided. Results Among 1039 patients screened, 847 patients met eligibility (ICC = 611, ECC = 236). Patients with ECC were more likely than those with ICC to present with early stage disease (53.8% vs 28.0%), undergo surgical resection (55.1% vs 29.8%), and receive adjuvant chemoradiation (36.5% vs 4.2%) (all P 
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/djad046